
Some promising news as Myeloma Awareness Month kicks off: the U.S. Food and Drug Administration (FDA) approved today a new therapy for patients with relapsed/refractory multiple myeloma. The approval provides an important new treatment option for patients with difficult-to-treat multiple myeloma. The new therapy, called isatuximab (Sarclisa®), is approved in combination with pomalidomide and dexamethasone for the treatment of adults with multiple myeloma who have received at least two pri...